• The number of prevalent cases of hemophilia A in the countries under study will remain relatively stable over the 20 years of our forecast period.
  • Of the countries considered in this analysis, the prevalence of hemophilia A is highest in France at 10.3 per 100,000.
  • 43/15/42% of all prevalent cases of hemophilia A in the countries under study have mild/ moderate/ severe disease.
  • The average age of all prevalent cases of hemophilia A in the countries under study is 36.
  • 97% of all prevalent cases of hemophilia A in the countries under study are male.

Table of contents

  • Hemophilia A - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Diagnosed Prevalence of Hemophilia A per 100,000 People of all Ages in 2020 and 2040
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Hemophilia A over the Next Twenty Years
      • Analysis of the Diagnosed Prevalent Cases of Hemophilia A in 2020 by Disease Subgroup
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Hemophilia A
      • Diagnosed Prevalent Cases by Severity
      • Diagnosed Prevalent Cases with inhibitor by Severity
      • Diagnosed Prevalent Cases with Inhibitor by Titer
      • Drug-Treated Prevalent Cases of Hemophilia A
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Hemophilia A
        • Studies Excluded from the Analysis of Hemophilia A
      • Risk/Protective Factors
        • Risk/Protective Factors for Hemophilia A
      • Bibliography

Author(s): Shilpa Thakur; Swarali Tadwalkar

Shilpa Thakur, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Before joining DRG, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.

Swarali joined Decision Resources Group (DRG) in 2016 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with her particular interests in the oncology space.

Prior to joining DRG, she has been extensively involved in primary and secondary healthcare research. Her experience involves projects in digital health, health policy and management, and health economics and outcomes research (HEOR). She has also coordinated various non-governmental public health projects focusing in hepatitis and human papilloma virus treatment access. Swarali holds a Masters in Public Health (Epidemiology) degree from the University of South Florida, Tampa.


Related Reports

Hemophilia - Landscape & Forecast - Disease Landscape & Forecast

Clarivate expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy opti...

View Details

Hemophilia - Current Treatment - Detailed, Expanded Analysis (EU)

Hemophilia A patients are a heterogeneous cohort. The tendency to bleed is highly individual, resulting in a complex management landscape. Two core therapeutic approaches are used: (1) prophylaxis,...

View Details

Hemophilia - Unmet Need - Detailed, Expanded Analysis : Hemophilia A – Severe Without Inhibitors: US/EU

The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatme...

View Details

Hemophilia | Disease Landscape and Forecast | Hemophilia A | G7 | 2020

DRG expects the next ten years to be transitional for patients with hemophilia A, with and without inhibitors, as both the number of therapy options and size of the hemophilia market increase. With...

View Details